Correspondence 0001437749-25-001732 from Monopar Therapeutics (MNPR)
Monopar Therapeutics
Date: Jan. 23, 2025 · CIK: 0001645469 · Accession: 0001437749-25-001732
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284304
Letter
mnpr20250122_corresp.htm
Monopar Therapeutics Inc.
1000 Skokie Blvd., Suite 350
Wilmette, Illinois 60091
January 23, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Monopar Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-284304
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Monopar Therapeutics Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to January 27, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
We request that we be notified of such effectiveness by a telephone call to John J. Harrington of Baker & Hostetler LLP, counsel to the Company, at (216) 861-6697 and that such effectiveness also be confirmed in writing.
Very truly yours,
Monopar Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm mnpr20250122_corresp.htm Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, Illinois 60091 January 23, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Monopar Therapeutics Inc. Registration Statement on Form S-3 File No. 333-284304 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Monopar Therapeutics Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to January 27, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. We request that we be notified of such effectiveness by a telephone call to John J. Harrington of Baker & Hostetler LLP, counsel to the Company, at (216) 861-6697 and that such effectiveness also be confirmed in writing. Very truly yours, Monopar Therapeutics Inc. By: /s/ Chandler D. Robinson Chandler D. Robinson Chief Executive Officer